摘要
血栓栓塞性疾病如深静脉血栓形成(DVT),肺栓塞(PE),心肌梗死(MI)和缺血性中风使人类发病率和死亡率增加,并已经严重影响到人们的世界各地的生活质量。据世界卫生组织统计,全球平均每年有1.7亿人死于血栓栓塞性疾病。因此,血栓栓塞性疾病的预防和治疗近年来受到广泛关注。基于血栓机制,抗血栓形成的药物主要分为抗凝药、抗血小板药和直接溶栓药物。抗凝剂如维生素K(vkas)、普通肝素 (UFH)和低分子量肝素 (LMWHs)成为治疗血栓栓塞性疾病的主要药物。然而,传统的抗凝药物起效慢、剂量调整的需求以及药物和药物、药物与食物之间的相互作用限制了该药物在临床治疗中疗效的提高。血栓栓塞性疾病的机制表明,凝血因子Xa(fXa)在凝血过程中起关键作用。因此,减少凝血酶的生成而不影响原有扩增凝血酶水平的FXa选择性抑制剂有着更好的抗血栓形成作用,从而减少原发性止血障碍。本文主要介绍了FXa抑制剂的研究进展,重点突出了其生物活性和构效关系(SAR)的信息,并特别强调了FXa抑制剂结构启示及其未来发展方向。
关键词: 抗凝药物,生物活性,F Xa,FXa抑制剂,凝血酶。
图形摘要
Current Drug Targets
Title:Advances in Inhibitors of FXa
Volume: 16 Issue: 11
Author(s): Liwei Guo and Shutao Ma
Affiliation:
关键词: 抗凝药物,生物活性,F Xa,FXa抑制剂,凝血酶。
摘要: Thromboembolic diseases such as deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (MI) and ischemic strokes are mainly responsible for people’s morbidity and mortality and have severely affected the people’s quality of life all over the world. According to WHO statistics, an average of 17 million people are killed by the thromboembolic diseases each year globally. Therefore, the prevention and treatment of thromboembolic diseases have received widespread attention in recent years. Based on thrombotic mechanism, anti-thrombotic drugs are mainly divided into anticoagulants, antiplatelet agents and direct thrombolytic drugs. In particular, anticoagulants such as vitamin K antagonists (VKAs), unfractionated heparin (UFH), and low-molecular-weight heparins (LMWHs) have become the main therapies for pre-treatment of thromboembolic disorders. However, the limitations of traditional anticoagulants such as slow onset of action, dose-adjusted requirement, drug-drug and drug-food interactions have restricted their improvement in the clinical treatment. The mechanism of the thromboembolic disorders has indicated that coagulation factor Xa (fXa) plays a pivotal role in the blood coagulation cascade. Thus, selective inhibition of fXa by diminishing the amplified generation of thrombin without affecting the pre-existing thrombin levels can provide better antithrombotic effect, thereby causing less impairment of primary hemostasis. In this paper, we mainly introduce the recent advances of fXa inhibitors, with focus on their biological activity and structure-activity relationship (SAR) information. In particular, the inspirations from the structures of the fXa inhibitors and their future direction are highlighted.
Export Options
About this article
Cite this article as:
Liwei Guo and Shutao Ma , Advances in Inhibitors of FXa, Current Drug Targets 2015; 16 (11) . https://dx.doi.org/10.2174/1389450116666150518095533
DOI https://dx.doi.org/10.2174/1389450116666150518095533 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptors Blockers on Mortality in Acute Heart Failure Patients with Left Ventricular Systolic Dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)
Current Vascular Pharmacology Current Inhibition Concepts of Zinc Metallopeptidases Involved in Blood Pressure Regulation
Current Enzyme Inhibition Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging Engineered Protein Protease Inhibitors
Current Enzyme Inhibition Multi-element Analyses and Chemical-physical Investigations of Food Samples
Current Nutrition & Food Science Reporting Rates of Yellow Fever Vaccine 17D or 17DD-Associated Serious Adverse Events in Pharmacovigilance Data Bases: Systematic Review
Current Drug Safety Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Current Drug Targets Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
Current Drug Metabolism Proniosomes in Transdermal Drug Delivery
Current Pharmaceutical Design An Update on the Immunological, Metabolic and Genetic Mechanisms in Drug Hypersensitivity Reactions
Current Pharmaceutical Design Mast Cell Disorders In Drug Hypersensitivity
Current Pharmaceutical Design Basophil Activation Test with Indomethacin to Assess Hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs: A Preliminary Study
Inflammation & Allergy - Drug Targets (Discontinued) Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury
Current Pharmaceutical Design Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
Current Clinical Pharmacology Genetic Engineering of Allergens for Immunotherapy
Inflammation & Allergy - Drug Targets (Discontinued) The Dietary Paradox in Food Allergy: Yesterday's Mistakes, Today's Evidence and Lessons for Tomorrow
Current Pharmaceutical Design Adverse Drug Reactions in the Oral Cavity
Current Pharmaceutical Design Strategies for Leukotriene Modulation in Dermatology: Current Evidence and Visionary Perspectives
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents IgE-Mediated Hypersensitivity to Cephalosporins
Current Pharmaceutical Design A Multicenter Study of IgE Sensitization to <i>Anisakis simplex</i> and Diet Recommendations
Endocrine, Metabolic & Immune Disorders - Drug Targets